Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01191775 · ClinicalTrials.gov registry record · Phase 1
A Study of PNT2258 in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Sierra Oncology LLC - a GSK company.
- Completed
- Registry status
- Phase 1
- Development phase
- 22
- Enrollment target
NCT01191775 is a Phase 1 study that has completed, run by Sierra Oncology LLC - a GSK company. The registered enrollment target is 22 participants.
The verdict
NCT01191775, a Phase 1 study, has completed, sponsored by Sierra Oncology LLC - a GSK company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 22 participants
- Enrollment target
Study Summary
This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. The purpose of this research study is to evaluate the safety of the investigational drug PNT2258 in patients with advance tumors and see how it acts in the body.
Interventions
- DRUG PNT2258
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2010-08 |
| Est. Completion | 2012-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01191775
The ClinicalTrials.gov registry entry for NCT01191775 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sierra Oncology LLC - a GSK company, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PNT2258 is the first listed.
NCT01191775 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01191775 about?
NCT01191775 is a clinical study titled "A Study of PNT2258 in Patients With Advanced Solid Tumors". This study is sponsored by Sierra Oncology, Inc. formerly ProNAi Therapeutics, Inc. The purpose of this research study is to evaluate the safety of the investigational drug PNT2258 in patients with advance tumors and see how it acts in the body.
What is the current status of trial NCT01191775?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 22 participants. The study started on 2010-08. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01191775?
The interventions under investigation include: PNT2258 (DRUG).
Who is sponsoring clinical trial NCT01191775?
This trial is sponsored by Sierra Oncology LLC - a GSK company, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.